Today: 17 May 2026
AMD stock slides as Big Tech’s AI spending boom meets fresh nerves on Wall Street
29 January 2026
1 min read

AMD stock slides as Big Tech’s AI spending boom meets fresh nerves on Wall Street

New York, January 29, 2026, 10:27 (EST) — Regular session

Advanced Micro Devices shares slipped 1.6% to $248.59 in Thursday morning trading, retreating from an earlier peak of $260.22. The stock lost $4.15 compared to its previous close.

The shift happened as U.S. tech shares took a hit. The Nasdaq dropped roughly 1% early on, dragged lower by Microsoft, which stumbled after cloud revenue missed expectations. That fueled fresh doubts about whether hefty AI investments are paying off quickly enough.

This debate hits home for AMD, whose chips power the servers behind AI. Capital expenditures on data centers and gear — or “capex” — are the key variable. Anthony Saglimbene, chief market strategist at Ameriprise Financial, said investors are looking for “very visible monetization or earnings.” Reuters

Microsoft’s figures added to the jitters. Shares dropped in Europe after the company revealed it poured a record sum into AI last quarter and reported slower growth in cloud computing, spooking investors fixated on short-term gains.

Meta shifted gears, raising its 2026 capital expenditure outlook to $115 billion-$135 billion amid its drive toward “superintelligence,” CEO Mark Zuckerberg told analysts. CFO Susan Li warned that capacity constraints will likely persist through much of 2026. Reuters

Chip shares surged the previous day on a growing AI wave. Positive cues from Texas Instruments and others pushed several names up. AMD, Nvidia, and Intel all gained as investors wagered that data-center demand is expanding past Nvidia’s top-tier processors.

Thursday saw a cooler mood across the sector. Nvidia slipped 1.6% to $188.48, while Intel dropped roughly 1.5%, closing at $48.05. AMD stayed roughly in line with the group’s movement.

But sentiment can shift fast. Software shares dropped following SAP’s cautious forecast for its cloud business and a sell-off in ServiceNow. Adam Turnquist of LPL Financial noted the market appears to be pricing in a “worst case scenario” — basically that “software is dead” as AI shakes up the sector. Reuters

AMD’s next major event is right around the corner. The company will release its fiscal fourth-quarter and full-year 2025 results after the market closes on Feb. 3, followed by a 5:00 p.m. EST conference call. CTO Mark Papermaster is also set to appear at Morgan Stanley’s Technology, Media & Telecom Conference on March 3.

Stock Market Today

  • Siemens Healthineers Valuation Review After Share Price Dip
    May 16, 2026, 8:04 PM EDT. Siemens Healthineers (XTRA:SHL) shares fell 2.1% in one day and 12.9% over the past month to €33.4, amid fading momentum and cooled investor sentiment. Despite the pullback, the stock trades at a roughly 38-58% discount to intrinsic value and analyst targets averaging €49.58-€53.47, suggesting potential undervaluation. Growth prospects are supported by rising demand for precision diagnostics amid aging populations and chronic disease trends. However, risks include tariff challenges and China's market weakness, which may pressure margins. Investors are advised to weigh key growth drivers against these risks when considering Siemens Healthineers for healthcare technology exposure.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Microsoft stock slides 10% after earnings beat as Azure outlook, AI bill unsettle Wall Street
Previous Story

Microsoft stock slides 10% after earnings beat as Azure outlook, AI bill unsettle Wall Street

Dow Jones today: DJIA edges up near 49,000 as AI spending scrutiny deepens
Next Story

Dow Jones today: DJIA edges up near 49,000 as AI spending scrutiny deepens

Go toTop